Omeros Co. (NASDAQ:OMER) Shares Sold by Stifel Financial Corp

Stifel Financial Corp lowered its position in Omeros Co. (NASDAQ:OMER) by 17.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,581,205 shares of the biopharmaceutical company’s stock after selling 323,002 shares during the period. Stifel Financial Corp owned 2.73% of Omeros worth $15,622,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Marshall Wace LLP acquired a new position in Omeros during the fourth quarter worth $437,000. XTX Topco Ltd acquired a new position in Omeros during the fourth quarter worth $206,000. Barclays PLC grew its holdings in Omeros by 9.6% in the 4th quarter. Barclays PLC now owns 103,726 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 9,086 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Omeros in the 4th quarter worth $124,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Tuesday, April 1st. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Trading Up 0.1 %

Shares of OMER opened at $7.31 on Friday. The company’s 50-day moving average price is $7.81 and its 200 day moving average price is $7.96. Omeros Co. has a 12-month low of $3.00 and a 12-month high of $13.60. The firm has a market cap of $424.45 million, a P/E ratio of -3.16 and a beta of 2.35.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter in the previous year, the company earned ($0.15) earnings per share. Equities research analysts forecast that Omeros Co. will post -3.09 earnings per share for the current year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.